Matches in SemOpenAlex for { <https://semopenalex.org/work/W4229445883> ?p ?o ?g. }
- W4229445883 endingPage "6" @default.
- W4229445883 startingPage "6" @default.
- W4229445883 abstract "To assess whether topical application of VEGFR1R2 Trap after corneal transplantation can impair corneal (lymph)angiogenesis and promote murine corneal allograft survival in eyes at high risk of rejection.We used the murine model of suture-induced neovascularization and subsequent keratoplasty in eyes at high risk of rejection, which is an established model for local drug application. After transplantation, the mice were treated with either VEGFR1R2 Trap (aflibercept) or human IgG Fc as eye drops for 2 weeks (three times/d). Deposition of VEGFR1R2 Trap in corneal tissue was detected by immunohistochemistry. Two and 8 weeks after transplantation, corneal (lymph)angiogenesis was assessed morphometrically. Dendritic cells (DCs) and regulatory T cells (Tregs) in the draining lymph nodes (dLNs) were examined by flow cytometry. Allograft survival was determined by corneal graft opacity scores.Topically applied VEGFR1R2 Trap penetrated into corneal host and graft stroma after keratoplasty in eyes at high risk of rejection. Additional postsurgical corneal hemangiogenesis (P < 0.0001) and lymphangiogenesis (P < 0.01) as well as infiltrating CD45+ leukocytes (P < 0.001) and macrophages (P < 0.01) were significantly reduced in the VEGFR1R2 Trap group compared to controls. VEGFR1R2 Trap eye drops significantly decreased the frequency of total CD11c+ DCs (P < 0.01), as well as activated CD11c+MHC II+ DCs (P < 0.01) and CD11c+CD40+ DCs (P < 0.05). In contrast, the frequency of CD200R+ regulatory DCs (P < 0.05) and Tregs in dLNs (P < 0.01) was enhanced. Moreover, long-term allograft survival was also improved (P < 0.05).Temporary, topical application of VEGFR1R2 Trap after corneal transplantation can achieve sufficient anti-VEGF activity, inhibit additional (lymph)angiogenesis, and significantly improve corneal allograft survival in eyes at high risk of rejection.VEGFR1R2 Trap eye drops after transplantation present a new therapeutic option for patients undergoing corneal transplantation and are at high risk of graft rejection." @default.
- W4229445883 created "2022-05-11" @default.
- W4229445883 creator A5057648240 @default.
- W4229445883 creator A5067633537 @default.
- W4229445883 creator A5076699095 @default.
- W4229445883 creator A5085296140 @default.
- W4229445883 date "2022-05-09" @default.
- W4229445883 modified "2023-09-26" @default.
- W4229445883 title "Posttransplant VEGFR1R2 Trap Eye Drops Inhibit Corneal (Lymph)angiogenesis and Improve Corneal Allograft Survival in Eyes at High Risk of Rejection" @default.
- W4229445883 cites W129369954 @default.
- W4229445883 cites W1518877530 @default.
- W4229445883 cites W164798711 @default.
- W4229445883 cites W1837370850 @default.
- W4229445883 cites W1964569584 @default.
- W4229445883 cites W1970189151 @default.
- W4229445883 cites W1970312470 @default.
- W4229445883 cites W1980725734 @default.
- W4229445883 cites W1982998490 @default.
- W4229445883 cites W1987885050 @default.
- W4229445883 cites W1996853317 @default.
- W4229445883 cites W2004646107 @default.
- W4229445883 cites W2009661102 @default.
- W4229445883 cites W2009868973 @default.
- W4229445883 cites W2009905145 @default.
- W4229445883 cites W2020801013 @default.
- W4229445883 cites W2022303441 @default.
- W4229445883 cites W2022985798 @default.
- W4229445883 cites W2025734854 @default.
- W4229445883 cites W2053926496 @default.
- W4229445883 cites W2065957571 @default.
- W4229445883 cites W2068557387 @default.
- W4229445883 cites W2070623276 @default.
- W4229445883 cites W2071980849 @default.
- W4229445883 cites W2074301535 @default.
- W4229445883 cites W2081461448 @default.
- W4229445883 cites W2090093512 @default.
- W4229445883 cites W2093044616 @default.
- W4229445883 cites W2132541143 @default.
- W4229445883 cites W2142266250 @default.
- W4229445883 cites W2160458616 @default.
- W4229445883 cites W2317446055 @default.
- W4229445883 cites W2324541703 @default.
- W4229445883 cites W2329123354 @default.
- W4229445883 cites W2399030352 @default.
- W4229445883 cites W2478469360 @default.
- W4229445883 cites W2512992000 @default.
- W4229445883 cites W2573539808 @default.
- W4229445883 cites W2600227851 @default.
- W4229445883 cites W2751025287 @default.
- W4229445883 cites W2787867562 @default.
- W4229445883 cites W2906014089 @default.
- W4229445883 cites W2918319988 @default.
- W4229445883 cites W2955238053 @default.
- W4229445883 cites W3095157598 @default.
- W4229445883 cites W3196812499 @default.
- W4229445883 cites W3216256615 @default.
- W4229445883 cites W40043819 @default.
- W4229445883 cites W829349618 @default.
- W4229445883 doi "https://doi.org/10.1167/tvst.11.5.6" @default.
- W4229445883 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35533080" @default.
- W4229445883 hasPublicationYear "2022" @default.
- W4229445883 type Work @default.
- W4229445883 citedByCount "0" @default.
- W4229445883 crossrefType "journal-article" @default.
- W4229445883 hasAuthorship W4229445883A5057648240 @default.
- W4229445883 hasAuthorship W4229445883A5067633537 @default.
- W4229445883 hasAuthorship W4229445883A5076699095 @default.
- W4229445883 hasAuthorship W4229445883A5085296140 @default.
- W4229445883 hasBestOaLocation W42294458831 @default.
- W4229445883 hasConcept C104317684 @default.
- W4229445883 hasConcept C118487528 @default.
- W4229445883 hasConcept C121608353 @default.
- W4229445883 hasConcept C126322002 @default.
- W4229445883 hasConcept C127716648 @default.
- W4229445883 hasConcept C141071460 @default.
- W4229445883 hasConcept C142724271 @default.
- W4229445883 hasConcept C203014093 @default.
- W4229445883 hasConcept C204232928 @default.
- W4229445883 hasConcept C2776636583 @default.
- W4229445883 hasConcept C2776882836 @default.
- W4229445883 hasConcept C2777844972 @default.
- W4229445883 hasConcept C2778271429 @default.
- W4229445883 hasConcept C2779013556 @default.
- W4229445883 hasConcept C2779720271 @default.
- W4229445883 hasConcept C2779919695 @default.
- W4229445883 hasConcept C2780394083 @default.
- W4229445883 hasConcept C2780686511 @default.
- W4229445883 hasConcept C2911091166 @default.
- W4229445883 hasConcept C502942594 @default.
- W4229445883 hasConcept C52124034 @default.
- W4229445883 hasConcept C55493867 @default.
- W4229445883 hasConcept C71924100 @default.
- W4229445883 hasConcept C86803240 @default.
- W4229445883 hasConceptScore W4229445883C104317684 @default.
- W4229445883 hasConceptScore W4229445883C118487528 @default.
- W4229445883 hasConceptScore W4229445883C121608353 @default.
- W4229445883 hasConceptScore W4229445883C126322002 @default.
- W4229445883 hasConceptScore W4229445883C127716648 @default.